Long-term safety study of acoramidis for newly diagnosed ATTR-CM
Treatments studied
Part of Brain & nervous system, Genetic & congenital, Heart & circulation, Hormones & metabolism, Mental health clinical trials.
This study follows people who completed an earlier trial of the drug acoramidis for a heart condition called ATTR-CM. It aims to check the long-term safety and how well people tolerate the drug.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have taken part in the earlier AG10-501 (ACT-EARLY) study and finished it within the last 60 days.
- You must have been diagnosed with ATTR-CM during that earlier study (not just the nerve condition ATTR-PN).
- You must not have a different type of amyloidosis (like AL) or abnormal proteins in your blood or urine that suggest AL.
- You must not have severe kidney disease (stage IV or V).
- You must not have an active cancer, except for certain skin or cervical cancers that were successfully treated.
- You must not have had an organ transplant (other than a cornea transplant) or be planning major surgery in the next 6 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial uses heart scans to see how the drug acoramidis affects heart structure and function in people with a specific type of heart disease called ATTR cardiomyopathy. It may help doctors understand if the treatment is working.
This trial tests a daily pill called acoramidis to see if it can prevent ATTR amyloidosis in people who carry a gene mutation but have no symptoms yet. It aims to stop the disease before it starts.
This study follows patients with a specific type of heart amyloidosis (wild-type ATTR) who are taking or could start the drug tafamidis. It aims to learn more about how the condition and treatment affect people over time.
This study looks at people who carry certain TTR gene variants, which can cause a specific type of heart amyloid buildup. It also includes people with symptoms, to understand how the condition develops and how it may be monitored.
This study is testing a medication called acoramidis for people with a heart condition called transthyretin amyloid cardiomyopathy (ATTR-CM). It aims to see how well the treatment works in a real-world setting in France.
This study follows people with a heart condition called transthyretin amyloid cardiomyopathy (ATTR-CM) who are starting treatment with acoramidis. It aims to see how well the medicine works in everyday medical practice.
Hear when a new Amyloidosis, Familial trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.